Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.79 |
| ▸ | JAK3 | P52333 | 3/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2508012 | 1.00 | EGFR (0.83) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL2510049 | 0.94 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2512053 | 0.92 | EGFR (0.81) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498590 | 0.92 | EGFR (0.76) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL17498589 | 0.92 | EGFR (0.76) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL19283327 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17538502 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2129369 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2512027 | 0.90 | EGFR (0.85) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2131418 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2248806-B1 | Quinazoline derivatives as tyrosine kinase inhibitors | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2013-04-24 | — | — | EP | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | EGFR 2954/4885ERBB2 2993/4885ERBB4 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.